Our Company

Jean-Pierre Gotteland, PhD

Chief Scientific Officer and Head of R&D

Jean-Pierre Gotteland joined ObsEva in September 2015 as Chief Scientific Officer and was also appointed Head of Research & Development in January 2018. He has over 20 years’ experience in the pharmaceutical industry in all product development stages, particularly in research, preclinical development and early clinical development.

After an early career at Pierre Fabre Medicament (France), he joined Serono in 1998 (subsequently Merck Serono) where he was responsible for various research and preclinical development programs in the areas of neurology, autoimmune disorders, endocrinology, metabolism and oncology. In 2007, he was one of the first employees to join PregLem, a Swiss based specialty biopharmaceutical company. As VP Non Clinical Development & CMC then Chief Development Officer, he actively contributed to the successful European registration of Esmya® (for the treatment of uterine fibroids), PregLem’s lead product, as well as to the progression of its development product portfolio.

Jean-Pierre holds a PhD in Organic Chemistry from the University Claude Bernard (Lyon, France) and an Engineering Diploma from Ecole Superieure de Chimie Industrielle (Lyon, France). He was a postdoctoral fellow at the University of Berkeley (California, USA), and he is the author and co-author of more than 40 publications and 30 patents.